Lamivudine News and Research

RSS
Switching from protease inhibitors to Nevirapine brings superior results for some HIV-infected children

Switching from protease inhibitors to Nevirapine brings superior results for some HIV-infected children

Switching to nevirapine drug from PI based regimen reduces viremia in children: Study

Switching to nevirapine drug from PI based regimen reduces viremia in children: Study

WHO revises treatment protocols for HIV patients

WHO revises treatment protocols for HIV patients

Gilead Sciences seeks MAA in Europe for fixed-dose combination of Truvada and TMC278 for HIV-1 infection

Gilead Sciences seeks MAA in Europe for fixed-dose combination of Truvada and TMC278 for HIV-1 infection

Long-term entecavir therapy suppresses HBV DNA, normalizes ALT and improves liver histology

Long-term entecavir therapy suppresses HBV DNA, normalizes ALT and improves liver histology

Long-term Entecavir therapy reverses fibrosis and cirrhosis in chronic hepatitis B patients

Long-term Entecavir therapy reverses fibrosis and cirrhosis in chronic hepatitis B patients

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

VBDS secondary to nevirapine use in HIV-positive, pregnant female: Report

VBDS secondary to nevirapine use in HIV-positive, pregnant female: Report

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Tibotec submits NDA for TMC278 anti-HIV compound to FDA

Tibotec submits NDA for TMC278 anti-HIV compound to FDA

Tibotec reports Phase 3 trial results of TMC278 vs. EFV in treatment-naive HIV-1-infected adults

Tibotec reports Phase 3 trial results of TMC278 vs. EFV in treatment-naive HIV-1-infected adults

Shionogi-ViiV Healthcare to advance '572 inhibitor into Phase III clinical trials

Shionogi-ViiV Healthcare to advance '572 inhibitor into Phase III clinical trials

Antiviral therapy prevents recurrence of HCC, extends patients' lives, researchers report

Antiviral therapy prevents recurrence of HCC, extends patients' lives, researchers report

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Kun Run Biotechnology obtains China SFDA manufacturing approval for Entecavir

Kun Run Biotechnology obtains China SFDA manufacturing approval for Entecavir

Infant nevirapine more effective in preventing HIV transmission than maternal antiretroviral therapy

Infant nevirapine more effective in preventing HIV transmission than maternal antiretroviral therapy

Gilead Sciences doses first patient in Quad Phase III clinical program

Gilead Sciences doses first patient in Quad Phase III clinical program

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective